Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Next Previous
Trial Profile

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Ciforadenant (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Corvus Pharmaceuticals

Most Recent Events

  • 28 Jul 2021 Status changed from recruiting to completed.
  • 31 May 2020 Results (n=82) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 29 May 2020 According to a Corvus Pharmaceuticals media release, from this study were presented at the ASCO20 Virtual Scientific Program.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top